Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

SLW: The part of dairy that is very well-positioned to assist consumers on their GLP-1 journey is yogurt. The functional benefits including protein, pre- and probiotics, variety of low and no sugar ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Working with a weight management program can help sustain the use of GLP-1 therapies and address potential side effects. Patient education and expectation management are crucial for maximizing ...

Sales of GLP-1 products were in-line with consensus. Guidance for 2025 is 16%-24% constant-currency sales growth plus a 3% currency tailwind. Why it matters: Novo's guidance for 2025 reflects ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

When Trova Wine and Market shut its doors last month after nearly five years in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like Ozempic.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...